These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35231159)

  • 1. Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [
    Schueller O; Skucas E; Regev G; Shaw I; Singh N; Sanghvi M; Croft M; Lohmer L; Alabanza A; Patel J
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):786-794. PubMed ID: 35231159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects.
    Schueller O; McDermott J; Evans P; Lohmer L; Alabanza A; Patel J
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):807-814. PubMed ID: 35238174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
    Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
    J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
    Schueller O; Willson A; Singh N; Lohmer L; Alabanza A; Patel J
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):795-806. PubMed ID: 35230741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
    Cutler C; Lee SJ; Arai S; Rotta M; Zoghi B; Lazaryan A; Ramakrishnan A; DeFilipp Z; Salhotra A; Chai-Ho W; Mehta R; Wang T; Arora M; Pusic I; Saad A; Shah NN; Abhyankar S; Bachier C; Galvin J; Im A; Langston A; Liesveld J; Juckett M; Logan A; Schachter L; Alavi A; Howard D; Waksal HW; Ryan J; Eiznhamer D; Aggarwal SK; Ieyoub J; Schueller O; Green L; Yang Z; Krenz H; Jagasia M; Blazar BR; Pavletic S
    Blood; 2021 Dec; 138(22):2278-2289. PubMed ID: 34265047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure of the Rho-associated coiled-coil kinase 2 inhibitor belumosudil bound to CK2α.
    Brear P; Hyvönen M
    Acta Crystallogr F Struct Biol Commun; 2022 Oct; 78(Pt 10):348-353. PubMed ID: 36189718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belumosudil for chronic graft-versus-host disease.
    Taylor B; Cohen J; Tejeda J; Wang TP
    Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a
    Singh RSP; Dowty ME; Salganik M; Brodfuehrer JI; Walker GS; Sharma R; Beebe JS; Danto SI
    Clin Pharmacol Drug Dev; 2022 Jul; 11(7):815-825. PubMed ID: 35506501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.
    Zanin-Zhorov A; Blazar BR
    Clin Immunol; 2021 Sep; 230():108823. PubMed ID: 34400321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belumosudil, ROCK2-specific inhibitor, alleviates cardiac fibrosis by inhibiting cardiac fibroblasts activation.
    Liu Q; Li HY; Wang SJ; Huang SQ; Yue Y; Maihemuti A; Zhang Y; Huang L; Luo L; Feng KN; Wu ZK
    Am J Physiol Heart Circ Physiol; 2022 Jul; 323(1):H235-H247. PubMed ID: 35657612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Excretion, and Mass Balance of [
    Ambery C; Young G; Fuller T; Lazaar AL; Pereira A; Hughes A; Ramsay D; van den Berg F; Daley-Yates P
    Clin Pharmacol Drug Dev; 2018 Nov; 7(8):901-910. PubMed ID: 30230263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
    Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
    Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.
    Lee SJ; Cutler C; Blazar BR; Tu A; Yang Z; Pavletic SZ
    Transplant Cell Ther; 2022 Oct; 28(10):700.e1-700.e6. PubMed ID: 35781099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belumosudil: First Approval.
    Blair HA
    Drugs; 2021 Sep; 81(14):1677-1682. PubMed ID: 34463931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
    Holmberg AA; Weidolf L; Necander S; Bold P; Sidhu S; Pelay-Gimeno M; de Ligt RAF; Verheij ER; Jauhiainen A; Psallidas I; Wählby Hamrén U; Prothon S
    Drug Metab Dispos; 2022 Feb; 50(2):150-157. PubMed ID: 34853068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [
    Burkard U; Desch M; Shatillo Y; Wunderlich G; Mack SR; Schlecker C; Teitelbaum AM; Liu P; Chan TS
    Clin Drug Investig; 2022 Jan; 42(1):87-99. PubMed ID: 34936055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
    Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
    Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
    Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers.
    Miah K; Vishwanathan K; Scarfe G; Li Y; Hara I; Cantarini M; Argue J; Menakuru SR
    Clin Pharmacol Drug Dev; 2023 Apr; 12(4):424-435. PubMed ID: 36808891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite.
    Bourdet DL; Yeola S; Hegde SS; Colson PJ; Barnes CN; Borin MT
    Drug Metab Dispos; 2020 Dec; 48(12):1312-1320. PubMed ID: 32978223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.